2,3,4-pentanetrione-3-[4-[[(4-dimethylaminophenyl)methylene]hydrazinocarbonyl]phenyl]hydrazone

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3,4-pentanetrione-3-[4-[[(4-dimethylaminophenyl)methylene]hydrazinocarbonyl]phenyl]hydrazone
• 英文别名: N-[(E)-[4-(dimethylamino)phenyl]methylideneamino]-4-[2-(2,4-dioxopentan-3-ylidene)hydrazinyl]benzamide
• 化学式: C₂₁H₂₃N₅O₃
• 分子量: 393.445
• InChiKey: KECAQVBGXXHKHZ-LPYMAVHISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  乙酰丙酮 、 4-Amino-benzoic acid [1-(4-dimethylamino-phenyl)-meth-(E)-ylidene]-hydrazide 在 盐酸 、 sodium nitrite 、 sodium acetate 作用下， 以 乙醇 、 水 为溶剂， 反应 24.0h， 以22%的产率得到2,3,4-pentanetrione-3-[4-[[(4-dimethylaminophenyl)methylene]hydrazinocarbonyl]phenyl]hydrazone
  参考文献：
  名称：

  Synthesis and antimycobacterial activity of some coupling products from 4-aminobenzoic acid hydrazones

  摘要：

  Various 2,3,4-pentanetrione-3- [4-[[(5 -nitro-2-furyl/pyridyl/substituted phenyl)methylene]hydrazinocarbonyl]phenyl] hydrazones 3a-j were synthesized by the reactions of acetylacetone with the diazonium salts of 4-aminobenzoic acid-[(5-nitro-2-furyl/pyridyl/substituted phenyl)methylene]hydrazides 2a-j at 0-5 degrees C. The structures of these compounds were determined using spectral data. All the synthesized compounds were evaluated for their antimycobacterial activity against Mycobacterium fortuitum ATCC 6841 and Mycobacterium tuberculosis H37Rv. Of the compounds screened, 2e, 2i, 3e and 3g were found to be active against M fortuitum at an MIC value of 32 mu g/mL. Compound 3a, which exhibited > 90% inhibition in the primary screen at 12.5 mu g/mL against M tuberculosis H37Rv, was the most promising derivative for antituberculosis activity. Results obtained from the level II screening showed that the actual MIC and IC50 values of 3a were 3.13 and 0.32 mu g/mL, respectively. The same compound was also tested against Mycobacterium avium, which was observed not to be susceptible to 3a. (C) 1999 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(99)00129-4